Silvercrest Asset Management Group LLC Acquires 55,622 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Silvercrest Asset Management Group LLC boosted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,511 shares of the biotechnology company's stock after purchasing an additional 55,622 shares during the quarter. Silvercrest Asset Management Group LLC owned about 0.22% of Arrowhead Pharmaceuticals worth $5,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of ARWR. Xponance Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 4.5% in the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock worth $327,000 after purchasing an additional 744 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock worth $714,000 after acquiring an additional 803 shares during the period. ADAR1 Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 10.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after buying an additional 1,195 shares during the period. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares during the last quarter. Finally, KBC Group NV raised its holdings in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 1,644 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ARWR shares. Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $42.13.

Arrowhead Pharmaceuticals Stock Down 1.7%

NASDAQ:ARWR traded down $0.26 during mid-day trading on Friday, reaching $15.13. The stock had a trading volume of 1,230,383 shares, compared to its average volume of 1,501,861. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -2.93 and a beta of 0.89. The stock's 50 day simple moving average is $13.32 and its two-hundred day simple moving average is $17.66. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the previous year, the firm earned ($1.02) earnings per share. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 275,880 shares of company stock valued at $4,034,037 over the last ninety days. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.